AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference
May 30 2018 - 6:30AM
AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on unmet medical needs in inflammation, today announced
that Hamza Suria, chief executive officer of AnaptysBio, will
present an overview of AnaptysBio at the Jefferies Global
Healthcare Conference on Wednesday, June 6, 2018 at 1:30 p.m. ET.
A webcast of the presentation will be available through the
investor section of the AnaptysBio website. A replay of the webcast
will be available for 90 days following the event.
About AnaptysBioAnaptysBio is a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation. The
company’s proprietary anti-inflammatory pipeline includes its
anti-IL-33 antibody (ANB020) for the treatment of
moderate-to-severe adult atopic dermatitis, moderate-to-severe
adult peanut allergy and severe adult eosinophilic asthma; its
anti-IL-36R antibody (ANB019) for the treatment of rare
inflammatory diseases, including generalized pustular psoriasis
(GPP) and palmoplantar pustulosis (PPP), previously referred to as
palmo-plantar pustular psoriasis; and a portfolio of checkpoint
receptor agonist antibodies for the treatment of certain autoimmune
diseases where immune checkpoint receptors are insufficiently
activated, which have demonstrated efficacy in an animal model of
graft-versus-host disease. AnaptysBio’s antibody pipeline has been
developed using its proprietary somatic hypermutation (SHM)
platform, which uses in vitro SHM for antibody discovery and is
designed to replicate key features of the human immune system to
overcome the limitations of competing antibody discovery
technologies. AnaptysBio has also developed multiple therapeutic
antibodies in an immuno-oncology partnership with TESARO and an
inflammation partnership with Celgene, including an anti-PD-1
antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody
(TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033), which
are currently under clinical development with TESARO, and an
anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the
clinic with Celgene.
Contact:Monique AllaireTHRUST Investor
Relations617.895.9511monique@thrustir.com
Chelcie ListerTHRUST Investor
Relations910.777.3049Chelcie@thrustir.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2023 to Apr 2024